| Brand names | Type | Strength (microg)* | Dose (inhalations) | Maximum dose† (inhalations) | Age restriction | PBS code | Authority code | Maximum quantity (2 repeats for all) | Actuations per device |
Rilast Rapihaler Symbicort Rapihaler | pMDI | 100/3 | 2 | 12 per occasion 16 per day 24 in one day temporarily | ≥ 12 years | 12042T | 10482 | 2 | 120 |
| Bufomix Easyhaler | DPI | 200/6 | 1 |
6 per occasion 8 per day 12 in one day temporarily | ≥ 12 years | 14166N 12041R | 10464 10464 | 2 1 | 60 120 |
Rilast Turbuhaler Symbicort Turbuhaler | DPI | 200/6 | ≥ 12 years | 12041R | 10464 | 1 | 120 | ||
| DuoResp Spiromax | DPI | 200/6 | ≥ 18 years | 12029D | 10464 | 1 | 120 |
Additional information
DPI: dry powder inhaler; pMDI: pressurised metered-dose inhaler; *Budesonide dose/formoterol dose; † Maximum doses as stated in TGA-approved product information (daily maximum rarely needed in practice)
TGA-approved indication: Anti-inflammatory reliever therapy is taken as needed for the relief of asthma symptoms when they occur, and as preventative treatment of symptoms in those circumstances recognised by the patient to precipitate an asthma attack. Patients should be advised to always have their anti-inflammatory reliever available for relief of symptoms. If the patient experiences a 3-day period of deteriorating symptoms after taking additional as needed inhalations, the patient should be reassessed for alternative explanations of persisting symptoms. Patient must not be on a concomitant single agent long-acting beta2 agonist. (Check PBS restrictions before prescribing)